Corvus PharmaceuticalsCRVS
Market Cap: $252M
About: Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Employees: 28
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
71% more call options, than puts
Call options by funds: $111K | Put options by funds: $65K
55% more capital invested
Capital invested by funds: $32.4M [Q1] → $50.2M (+$17.9M) [Q2]
7.05% more ownership
Funds ownership: 37.06% [Q1] → 44.11% (+7.05%) [Q2]
0% more funds holding
Funds holding: 47 [Q1] → 47 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
0% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 11
Research analyst outlook
We haven’t received any recent analyst ratings for CRVS.
Financial journalist opinion
Based on 3 articles about CRVS published over the past 30 days